#COVID-19 : Adoption of the temporary reduction from 25% to 10% of the capital holding threshold, triggering the control of foreign investments
On July 29, 2020 By Jérémy BERNARD
1. During a hearing before the Economic Affairs Committee of the French National Assembly on 29 April 2020 and in a press release published the following day, Bruno Lemaire, then French Minister of Economic Affairs and Finance, had announced modifications of the rules governing the French foreign investment control mechanism to adapt them to the current pandemic of COVID-19. This included a reduction from 25% to 10% of the threshold for holding the capital or voting rights of a French listed undertaking (see our article issued on 30 april 2020 regarding this matter).
2. As a reminder, transactions meeting the three following cumulative conditions fall under the French foreign investment control mechanism:
(i) the direct or indirect acquisition of
(a) the control of a business having its registered office in France,
(b) all or part of a branch of activity of a business having its registered office in France, or
(c) a share of the capital or voting rights in a business having its registered office in France when this acquisition results in meeting a threshold of 25% of the capital or voting rights of this business;
(ii) by an investor from another State whether or not it is a Member State of the European Union or the European Economic Area, except in the case of an acquisition mentioned in 2.(i)(c) above for which only an investor from a third party State to the European Union or the European Economic Area falls within the scope of the control mechanism; and
(iii) insofar as the target exercises a so-called “sensitive” activity, the activities qualified as “sensitive” being listed in Articles L. 151-3 and R. 151-3 of the French Monetary and Financial Code and including e.g. the manufacture and trade of war materials and dual-use goods, computer security, cryptology, gambling (excluding casinos), data storage, water or energy supply networks, transport or electronic communications networks and services, agricultural business, the press or the research and development on critical technologies.
3. By French Decree No. 2020-892 of 22 July 2020, the 25% threshold mentioned in 2.(i)(c) above was lowered to 10% of the capital or voting rights of an undertaking having its registered office in France and which shares are admitted to trading on a regulated market. This reduction is temporary and, due to an express provision of the Decree, will automatically cease to apply on 31 December 2020 at midnight.
4. In addition, foreign investments benefit from an expedited procedure for their clearance when meeting this new temporary 10% threshold but remaining below the permanent 25% threshold and having to be closed within six months from their notification to the Minister in charge of economic affairs. They are deemed to be authorized if within ten days from the reception of this notification, the Minister has not objected the project. The practical details of this expedited procedure have yet to be defined by a French Order of the Minister in charge of economic affairs.
Our latest news
Coordination of pension schemes: what legal framework applies to international careers?
International workforce mobility involves a complex interplay between several national social security systems. In terms of retirement, this raises major legal questions: which legislation applies to a posted or expatriate employee? How are their acquired rights preserved from one country to another? Under what terms will their pension ultimately be settled? These are questions our […]
Read
Shadow Payroll and International Assignments in France: a compliance guide for foreign employers
Foreign companies deploying employees or executives to France face a layered set of obligations that span employment law, payroll reporting, taxation, social security coordination, and immigration procedures. Managing these requirements in isolation — through separate providers across different jurisdictions — often leads to gaps, duplications, or costly errors. DELCADE’s International Assignment Services practice offers a […]
Read
DELCADE advises Geistlich Pharma AG on taking control of OST Développement
The European regenerative medicine market continues to consolidate. On 24 April 2026, the Swiss group Geistlich Pharma AG completed the acquisition of a majority stake in OST Développement, a French specialist in bone regeneration. DELCADE acted as legal counsel to the acquirer, extending a collaboration that began back in 2024. A two-stage M&A move The […]
Read